About Antithrombin-III
Antithrombin-III (SERPINC1) is a protein
from Homo sapiens identified by UniProt accession
P01008, 464 residues long.
MolForge cross-references it against 0 known binders and
652 disease associations.
Target properties
| Protein name | Antithrombin-III |
| UniProt accession | P01008 |
| Gene | SERPINC1 |
| Organism | Homo sapiens |
| Length | 464 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (652)
Diseases linked to this target (Open Targets).
- hereditary antithrombin deficiency · score 0.85
- Venous thrombosis · score 0.71
- venous thromboembolism · score 0.66
- deep vein thrombosis · score 0.65
- pulmonary embolism · score 0.60
- atrial fibrillation · score 0.60
- myocardial infarction · score 0.60
- Reduced antithrombin III activity · score 0.59
- COVID-19 · score 0.58
- Thromboembolism · score 0.58
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01008-F1 | alphafold | PREDICTED | 84.68 | — |
Amino-acid sequence (464 residues)
MYSNVIGTVT SGKRKVYLLS LLLIGFWDCV TCHGSPVDIC TAKPRDIPMN PMCIYRSPEK KATEDEGSEQ KIPEATNRRV WELSKANSRF ATTFYQHLAD SKNDNDNIFL SPLSISTAFA MTKLGACNDT LQQLMEVFKF DTISEKTSDQ IHFFFAKLNC RLYRKANKSS KLVSANRLFG DKSLTFNETY QDISELVYGA KLQPLDFKEN AEQSRAAINK WVSNKTEGRI TDVIPSEAIN ELTVLVLVNT IYFKGLWKSK FSPENTRKEL FYKADGESCS ASMMYQEGKF RYRRVAEGTQ VLELPFKGDD ITMVLILPKP EKSLAKVEKE LTPEVLQEWL DELEEMMLVV HMPRFRIEDG FSLKEQLQDM GLVDLFSPEK SKLPGIVAEG RDDLYVSDAF HKAFLEVNEE GSEAAASTAV VIAGRSLNPN RVTFKANRPF LVFIREVPLN TIIFMGRVAN PCVK
Explore Antithrombin-III with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets